United Kingdom Amlodipine Besylate Market Insight
Published: 26 May 2026 | Report Format: Electronic (PDF)
The UK amlodipine besylate market is rapidly expanding, at a 5.04% CAGR, and the hypertension prevalence, ageing population, and NHS prescriptions
UK Amlodipine Besylate Market Insights Forecasts to 2035
- The UK Amlodipine Besylate Market Size Was Estimated at USD 37.5 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.04% from 2025 to 2035
- The UK Amlodipine Besylate Market Size is Expected to Reach USD 61.3 Million by 2035
Notable Insights into the UK Amlodipine Besylate Market
- Tab forms contribute up to 81% market share of the United Kingdom amlodipine besylate market due to NHS preference in prescribing oral hypertension medications, facilitated by investment in the order of £1.5Billion towards generic production and cardiovascular medication accessibility programs.
- The hypertension holds 68% market demand for amlodipine besylate in the UK, backed by growing incidences of heart diseases and NHS screening programs, supported by £2Billion investments towards chronic disease management and expanding pharmaceutical sector.
- There are more than 14 million adults suffering from hypertension in the United Kingdom, resulting in high market demand for amlodipine besylate, facilitated by investments in excess of £2.5Billion towards NHS cardiovascular care, screening, and chronic disease management pharmaceutical programs.
Download the eBook (ToC)
- The National Health Service in the United Kingdom spends more than £180Billion annually, allowing easy availability of cardiovascular drugs including amlodipine besylate, facilitated by investments in excess of £3Billion towards chronic disease treatment and pharmaceutical sector.
Research Methodologies Used to Analyze the UK Amlodipine Besylate Market
The United Kingdom amlodipine besylate market research combines 75% secondary data from NHS publications, regulatory databases, prescription trends, and pharmaceutical reports with 25% primary insights from UK cardiologists, hospital procurement teams, pharmacists, and distributors. This structured methodology is supported by healthcare analytics and pharmaceutical research investments, ensuring accurate cardiovascular treatment forecasting, demand assessment, and evidence-based market intelligence.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the UK amlodipine besylate market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in UK Amlodipine Besylate Market
- Pfizer
- Teva Pharmaceutical Industries
- Viatris
- Accord Healthcare
- Sandoz
- Sun Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Aurobindo Pharma
- Others
Recent Developments:
- In March 2026, Viatris strengthened cardiovascular drug supply in the United Kingdom amlodipine besylate market, enhancing NHS access to generics. Supported by £2Billion pharmaceutical distribution investments, it improves hypertension treatment affordability and healthcare system efficiency.
- In October 2025, Teva Pharmaceutical Industries strengthened generic cardiovascular supply in the United Kingdom amlodipine besylate market, enhancing NHS affordability and access. Supported by £2.5Billion global generic investments, it boosts hypertension treatment availability and healthcare efficiency.
Market Segmentation:
United Kingdom Amlodipine Besylate Market, By Dosage Form
- Tablets
- Capsules
- Oral Suspension
- Others
United Kingdom Amlodipine Besylate Market, By Application
- Hypertension
- Angina
- Coronary Artery Disease
- Others
United Kingdom Amlodipine Besylate Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
United Kingdom Amlodipine Besylate Market, By End User
- Hospitals
- Clinics
- Homecare Settings
- Others
Expert Views:
The UK amlodipine besylate market forecast suggests a steady growth trend due to increasing instances of hypertension, aging population, and the use of cardiovascular disease prevention strategies. Efficient management of chronic conditions by NHS, availability of inexpensive generics, and blood pressure screening support the market
Author: Aditi and Govind By Spherical Insights and Consulting